poster

The Incidence and Economic Burden of Extrapyramidal Symptoms in Patients with Schizophrenia Treated with Atypical Antipsychotics

Background: Extrapyramidal symptoms (EPS), including movement disorders, tremors, and muscle contractions are common side effects of atypical antipsychotic (AAP) drugs in patients with sc...

10/08/2020

Safety and Effectiveness of SEP-363856 in Schizophrenia: Results of a 6-month, Open-label Extension Study

Background: SEP-363856 is a novel non-D2 receptor antagonist, and preclinical data suggest that agonism at trace amine associated receptor 1 (TAAR1) and the serotonin 5-H1A receptor contr...

10/08/2020

Reduction in Anxiety Symptoms in Patients With Postpartum Depression (PPD) Treated With the Neuroactive Steroid Brexanolone Injection (BRX)

Background: Anxiety is a prominent symptom and comorbidity of PPD. Post-hoc analyses of an integrated dataset from three BRX PPD trials evaluated effects of BRX on anxiety symptoms using ...

10/08/2020

The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System

Objective: A previous study demonstrated that patients with schizophrenia consumed substantial healthcare resources in an integrated healthcare system. This study evaluated healthcare uti...

10/08/2020

Safety and Effectiveness of SEP-363856 in Schizophrenia: Results of a 6-month, Open-label Extension Study

Background: SEP-363856 is a novel non-D2 receptor antagonist, and preclinical data suggest that agonism at trace amine associated receptor 1 (TAAR1) and the serotonin 5-H1A receptor contr...

10/08/2020

The Clinical Implications of Weight Gain on Depression and Anxiety in Mental Health Treatment

Individuals with severe mental illness are at increased risk for weight gain due to side effects from atypical antipsychotics and mood stabilizers, sedentary lifestyle, and social isolati...

10/08/2020

The Clinical Utility of Combinatorial Pharmacogenomic Testing for Patients with Depression: A Meta-Analysis

Background: Pharmacogenomic (PGx) testing is a potential tool to inform clinicians’ treatment decisions for patients with Major Depressive Disorder (MDD). However, there is mixed evidence...

10/08/2020

Response to Pimavanserin Treatment in Patients With Dementia-related Psychosis: Results From the 12-Week, Open-label Phase of the HARMONY Study

Dementia-related psychosis (DRP) is common in patients with Alzheimer‚Äôs disease (AD), dementia with Lewy bodies (DLB), Parkinson‚Äôs disease dementia (PDD), vascular dementia (VaD), and...

10/08/2020

Weight Gain and Treatment Interruptions With Second-Generation Oral Antipsychotics: Analysis of Real-World Data Among Patients With Schizophrenia or Bipolar I Disorder

Among patients with schizophrenia (SZ) and bipolar I disorder (BD-I) treated with second-generation antipsychotics (SGAs), clinically-significant weight gain (CSWG) and treatment interrup...

10/08/2020

Somnolence and Sedation with Lumateperone Treatment: A Comparison of Morning and Evening Administration

Background: Somnolence and sedation are common treatment-emergent adverse events (TEAEs) reported with current antipsychotics. Lumateperone (lumateperone tosylate, ITI-007), a mechanistic...

10/08/2020

Tracks

MDD Insights

Schizophrenia Insights

Major Depressive Disorder

General Psychiatry

ADHD

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products